Donor derived regulatory T lymphocytes and the JAK1/2 kinase inhibitor ruxolitinib are currently
being evaluated as therapeutic options in the treatment of chronic graft versus host disease (cGvHD).
In this work, we aimed to determine if the combined use of both agents can exert a synergistic efect
in the treatment of GvHD. For this purpose, we studied the efect of this combination both in vitro
and in a GvHD mouse model. Our results show that ruxolitinib favors the ratio of thymic regulatory T
cells to conventional T cells in culture, without afecting the suppressive capacity of these Treg. The
combination of ruxolitinib with Treg showed a higher efcacy as compared to each single treatment
alone in our GvHD mouse model in terms of GvHD incidence, severity and survival without hampering
graft versus leukemia efect. This benefcial efect correlated with the detection in the bone marrow of
recipient mice of the infused donor allogeneic Treg after the adoptive transfer
